相关实验视频
Updated: Sep 12, 2025

09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.8K
在糖尿病病中SGLT2抑制剂和塞马格卢提德的比较有效性:一项回顾性观察性研究
1Internal Medicine, Aster DM Healthcare, Dubai, ARE.
Cureus
|August 7, 2025
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂和类似葡萄糖类-1 (GLP-1) 受体激动剂在2型糖尿病中对脏有好处. 这两种药物都改善了功能,对治疗糖尿病病有互补作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 通常导致糖尿病病.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂和葡萄糖类-1 (GLP-1) 受体激动剂提供了超出血糖控制的保护.
- 需要个性化治疗策略,以最佳管理糖尿病病.
研究的目的:
- 为了比较SGLT2抑制剂与早期糖尿病脏病患者GLP-1受体激动剂的和代谢作用.
- 评估这两种药物类别的互补性脏保护特征.
主要方法:
- 一个10名患有早期糖尿病病的患者的比较系列.
- 五名患者接受了SGLT2抑制剂 (empagliflozin或dapagliflozin) 的治疗.
- 五名患者接受了塞马格卢提德 (一种GLP-1受体激动剂) 治疗.
- 六个月的随访期.
主要成果:
- 无论是SGLT2抑制剂还是西马格卢提德,都改善了白蛋白尿和稳定了估计的淋巴膜过率 (eGFR).
- 塞马格卢提德组的体重和HbA1c的减少更大.
- SGLT2 抑制剂组表现出较为一致的白尿下降.
- 这两种药物类别都被很好地容忍.
结论:
- 在T2DM中,SGLT2抑制剂和GLP-1受体激动剂具有互补的保护性质.
- 个人使用这些药物是支持管理糖尿病病的.
- 进一步的随机试验是必要的,以探索最佳的测序或组合疗法.
相关概念视频
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
Oral Hypoglycemic Agents: Sulfonylureas
332
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
332
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K

